Skip to main content
Equibles
LEEEF logo

LEEEF · Leef Brands Inc. · Metrics

Track LEEEF — free

Use LEEEF with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research LEEEF.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.16 -0.01 (-3.18%) At close · Nov 5
Rebalance outlook locked
Going-concern doubt — flagged Aug 6, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Such uncertainties related to events and conditions raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans to address these conditions include the equity financings described in Note 19 and Note 24, which raised aggregate gross proceeds of approximately $14.2 million through July 2026, the continued benefit of vertically integrated biomass supply from Salisbury Canyon Ranch on the Company’s gross margins, and continued discipline over operating costs.”
View the 10-Q filed Aug 6, 2026
Market Cap
$50.42M
Shares
305.56M
Volume · Nov 5 139.75K Avg daily vol (3M) 207.27K

LEEEF metrics

59 of 125 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.16
Market cap
$50.42M

Price action

23 metrics
Price change (1W)
+16.2%
Price change (30D)
-6.4%
Price change (3M)
-12.3%
Price change (6M)
-0.2%
Price change (YTD)
+5.5%
Price change (1Y)
-16.9%
Trailing year
Price change (5Y)
-39.3%
52-week high
$0.22
52-week low
$0.11
Change from 52-week high
-25.9%
Change from 52-week low
+52.4%
Annualized volatility
76.9%
Annualized volatility (3M)
55.2%
Implied volatility (30D)
—
IV rank (1Y)
—
IV percentile (1Y)
—
Beta
0.3
RSI (14D)
52.5
Price vs SMA 50
-5.3%
Price vs SMA 200
-3.1%
Avg volume (3M)
207,267
Relative volume
0.7
Average dollar volume
$36,153

Company

3 metrics
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
305.56M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
1.5×
reciprocal yield 66.1%
P / book
—
FCF yield
-7.5%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-33.2%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
41.8%
Operating margin
-12.0%
Trailing 12 months
Net margin
-50.1%
Gross profit (TTM)
$13.95M
Operating profit (TTM)
−$4.01M
Net income (TTM)
−$16.72M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
-11.3%
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-0.03

Growth

11 metrics
Revenue growth YoY
-16.3%
Year over year
Net income growth YoY
—
Revenue (TTM)
$33.35M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+65.3%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-31.9%
Debt / equity
—
Current ratio
2.1
EBITDA (TTM)
−$2.72M
Free cash flow (TTM)
−$3.77M
Quick ratio
1.2
Interest coverage
-2.3
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$4.95M
Latest balance sheet
Cash & equivalents
$4.95M
Total assets
$52.41M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$1.97M
Capital expenditures (TTM)
$1.79M
R&D (TTM)
$8,860
SG&A (TTM)
—
Stock compensation (TTM)
$2.79M
R&D / revenue
0.0%
Stock compensation / revenue
8.4%

Ownership (13F)

9 metrics
13F filers
—
13F filer change QoQ
—
Institutional ownership
—
Conviction holders (share of 13F filers)
—
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
—
Holder tenure
—
Price vs estimated holder cost
—

Ownership (registered funds)

1 metrics
Index-fund ownership
0.0%

Short interest

3 metrics
Short interest
0.1%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
45 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1711141 CUSIP 52426X203 Visit website Investor relations